Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

47.88 +1.59 (+3.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
Vertex already generates billions in revenue -- but there may be more to come. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics
Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter: 
Via Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
2 Cathie Wood Stocks That Are Beating the Market This Year
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
Exposures Product Safety
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash. 
Via Benzinga
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market
Vertex flashed a buy signal on positive gene-editing news. 
Via Investor's Business Daily
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
What Is Going on With Grom Social (GROM) Stock Today?
Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media. 
Via InvestorPlace
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today?
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today! 
Via InvestorPlace
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. 
Via InvestorPlace
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug
Crispr and Vertex nailed down the timeline for their blood diseases gene editor. 
Via Investor's Business Daily
Why CRISPR Therapeutics Stock Is Rising Today
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S. 
Via Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
No One Told These 3 Stocks It’s a Down Week
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space. 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit. 
Via InvestorPlace
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile. 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today
  CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
  
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.